People: ReNeuron Group PLC (RNUGF.PK)

RNUGF.PK on OTC Markets Group - US Other OTC and Grey Market

0.03USD
19 Mar 2013
Price Change (% chg)

$-0.02 (-40.00%)
Prev Close
$0.05
Open
$0.03
Day's High
$0.03
Day's Low
$0.03
Volume
50,000
Avg. Vol
117
52-wk High
$0.08
52-wk Low
$0.01

Search Stocks

Summary

Name Age Since Current Position

Bryan Morton

 56 2011 Non-Executive Chairman of the Board

Michael Hunt

 49 2005 Chief Executive Officer, Executive Director

John Sinden

 61 Chief Scientific Officer, Executive Director

Patrick Huggins

 2011 Company Secretary

John Berriman

 65 2011 Non-Executive Director

Simon Cartmell

 2011 Non-Executive Director

Tim Corn

 61 2012 Non-Executive Director

Mark Docherty

 48 2003 Non-Executive Director

Paul Harper

 66 Non-Executive Director
» Insider Trading

Biographies

Name Description

Bryan Morton

 Mr. Bryan Geoffrey Morton, BSc, MBA, is Non-Executive Chairman of the Board of ReNeuron Group plc. Mr. Morton is Chief Executive Officer of EUSA Pharma, Inc., a growing specialty pharmaceutical company he founded in 2006. He is a non executive director of Dechra Pharmaceuticals plc, Aircraft Medical Ltd and is a member of the Pilgrim Software global advisory board. He began his pharmaceutical career in sales and has held positions in medical information, marketing, sales management, business development and general management during a 30 year career in the healthcare industry, largely with Merck and Co. Inc. and Bristol Myers Squibb. In 2003, he founded Zeneus Pharma, which was sold to Cephalon Inc. in late 2005 for US$360 million. He has a BSc in Pharmacology from Aberdeen University and a MBA from Durham University.

Michael Hunt

 Mr. Michael Elliott Hunt, BSc ACA, is Chief Executive Officer, Executive Director of ReNeuron Group Plc. He joined the Company as Chief Financial Officer and was appointed Chief Operating Officer in September 2003 and Chief Executive Officer in July 2005. Prior to the Company, he spent six years at Biocompatibles International plc where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He is a founding member of the Biolndustry Association’s RegenMed Industry Group Advisory Committee and is a Senior Industry Group member the UK Government’s recently established Office for Life Sciences. He read economics at University College London and qualified a chartered accountant with Ernst & Young in London.

John Sinden

 Dr. John D. Sinden, BA, MA, Ph.D., is Chief Scientific Officer, Executive Director of ReNeuron Group Plc. Prior to joining ReNeuron as Chief Scientific Officer in October 1998, he was Reader in Neurobiology of Behaviour at the Institute of Psychiatry at Kings College London. He graduated in Psychology from the University of Sydney and completed a Ph.D. in Neuroscience from the University of Paris at the College de France. He subsequently held post-doctoral appointments at Oxford University and the Institute of Psychiatry prior to joining the permanent staff of the Institute in 1987. Dr. Sinden is a member of the Royal Society of Medicine, the Society for Neuroscience and the International Society for Cellular Therapies. He sits on the Industry Committee of the International Society for Stem Cell Research, the Scientific Advisory Board of the Minda de Gunzburg Center for Ocular Regeneration, Schepens Eye Research Institute at Harvard Medical School, and Gene Therapies for the Bioindustry Organization BioSafe Committee.

Patrick Huggins

 Mr. Patrick Huggins is Company Secretary of ReNeuron Group Plc. He was appointed as Head of Finance and Company Secretary in May 2010 having previously worked for ReNeuron in an interim capacity. He qualified as a Certified Accountant in 1984 and has spent the majority of his career in growth companies within the SME sector.

John Berriman

 Mr. John Edward Berriman, BEng, MBA, is Non-Executive Director of ReNeuron Group PLC. He is the Chairman of Heptares Therapeutics Ltd, Pronota NV and past Chairman (now deputy Chairman) of Algeta ASA (listed on the Oslo stock exchange). He is also a non-executive director of MicroMet, Inc. (listed on NASDAQ). Previously he was a director of Abingworth Management, an international healthcare venture capital firm, where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA – many of which obtained listings on public stock exchanges. Prior to that, he spent 14 years with Celltech Group plc and was a member of its Board when it listed on the London Stock Exchange in 1994. He has a degree in Chemical Engineering from the University of Cambridge and an MBA from the London Business School. In addition to the positions mentioned above, he has in the last five years been a non-executive director of Ablynx NV and Oxxon Therapeutics Holdings, Inc.

Simon Cartmell

 Mr. Simon Cartmell, BSc, MSc, is Non-Executive Director of ReNeuron Group PLC. Its sale to Baxter International Inc for $330m was completed in March 2010. Prior to ApaTech he was CEO of Celltech Pharmaceuticals and a director of Celltech Group plc. Before that, he was Chief Operating Officer of Vanguard Medical plc. His early career was spent at Glaxo plc in multiple senior UK and global commercial strategy, product development, supply chain, marketing, sales and business development roles. He is a Medical Microbiology graduate from Manchester University and an alumnus of the London Business School Sloan Fellowship Programme. He is currently Executive Chairman of OSspray Ltd, an emerging dental company, and he is also a non-executive director of Phase4 Ventures, an adviser to the MTI/University of Manchester Premier Fund and to several emerging life science and medical technology companies in the UK and internationally.

Tim Corn

 Dr. Tim Corn, MSc, FFPM, FRCPsych, is Non-Executive Director of ReNeuron Group plc. He is Chief Medical Officer at EUSA Pharma International, a division of Jazz Pharmaceuticals, and was formally CMO at EUSA Pharma Inc, until its acquisition by Jazz in 2012, and CMO at Zeneus Pharma, which was acquired by Cephalon Inc in 2006. In addition, he serves as Non-executive Director on the Board of Circassia Limited, a clinical-stage development company working in the field of immunology. Dr. Corn qualified in medicine at King’s College Hospital, London after gaining a Master’s degree in biochemistry from Imperial College. He became consultant and senior lecturer in neuropsychiatry at the Institute of Psychiatry, London, and is the author of more than forty scientific publications. Dr Corn has held senior clinical and regulatory positions at GlaxoWellcome, MSD Research Laboratories, Athena Neuroscience and Elan as well as in the UK regulatory agency. He has played a key role in twenty regulatory approvals in USA and Europe for products in the fields of neurology and oncology, the most recent being the approval by FDA of the BLA for Erwinaze™. He was elected Fellow of the Faculty of Pharmaceutical Medicine in 1996 and of the Royal College of Psychiatrists in 1998.

Mark Docherty

 Mr. Mark Docherty, BEng, FCA, is Non-Executive Director of ReNeuron Group Plc. He is Finance and Corporate Director of FKD Therapies Oy, a Finnish based gene therapy company whose lead product for bladder cancer is in clinical development. He is also Chief Financial Officer of Woelbern Private Equity GmbH, a specialist private equity house. He was a founding director of Merlin Biosciences Limited (now Excalibur Fund Managers Limited) and was actively involved in the structuring and financing of many of the Merlin portfolio companies including ReNeuron. Previously, he was a Manager in the Corporate Finance Group of Arthur Andersen. He is a chartered accountant and holds a BEng in Mechanical Engineering from Sheffield University. He is also a non-executive director of CBT Development Limited and Pantherix Limited.

Paul Harper

 Dr. Paul Bernard Harper, BSc, Ph.D., is Non-executive Director of ReNeuron Group Plc. Dr Harper is a graduate of Leeds University (Microbiology/Virology). He initially pursued a career in drug discovery and development with Glaxo Group Research as Head of Antimicrobial Chemotherapy, Johnson & Johnson Limited as Director of R&D and with Unipath plc. This was followed by work in a number of startup companies and SMEs as Chief Executive Officer or adviser. These included, as CEO, preparing Cambridge Antibody Technology PLC for flotation on the London Stock Exchange and founding Provensis Limited to develop a drug device product. Currently Chairman of Angel Biotechnology plc, Physiomics plc, Sareum Holdings plc and three other private biotechnology/devices businesses.

Basic Compensation

Name Fiscal Year Total

Bryan Morton

 29,000

Michael Hunt

 238,000

John Sinden

 222,000

Patrick Huggins

 --

John Berriman

 --

Simon Cartmell

 --

Tim Corn

 --

Mark Docherty

 --

Paul Harper

 --
As Of 30 Mar 2012

Options Compensation

Name Options Value

Bryan Morton

 0 0

Michael Hunt

 0 0

John Sinden

 0 0

Patrick Huggins

 0 0

John Berriman

 0 0

Simon Cartmell

 0 0

Tim Corn

 0 0

Mark Docherty

 0 0

Paul Harper

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks